Reportedly, both the companies are expected to shortly initiate a technical evaluation of several Microbidex product formulations for their utility against human topical fungal infections.
Once the evaluation period is complete, in approximately nine months time, the parties plan to enter into a formal agreement to pursue the development, regulatory approval, commercialisation, marketing and distribution of these and other products throughout North America.
Lois Rosenberger, president of LBR Regulatory & Clinical Consulting Services, said: “This alliance between Microbide and LBR Regulatory will progress the ability to develop and commercialise meaningful products to meet the needs of patients with these issues, in the North American market, many of whom are on poly-therapies or otherwise unsuitable for oral medication.”